Liisa Bayko

Stock Analyst at Evercore ISI Group

(3.64)
# 826
Out of 5,041 analysts
85
Total ratings
56.34%
Success rate
25.72%
Average return

Stocks Rated by Liisa Bayko

Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20$12
Current: $10.50
Upside: +14.29%
Vertex Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $510$475
Current: $421.39
Upside: +12.72%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280$515
Current: $463.43
Upside: +11.14%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3$2
Current: $4.36
Upside: -54.13%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60$99
Current: $67.61
Upside: +46.43%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33$45
Current: $28.06
Upside: +60.37%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10$12
Current: $7.20
Upside: +66.67%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7$5
Current: $3.72
Upside: +34.41%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30$35
Current: $38.93
Upside: -10.10%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405$360
Current: $421.50
Upside: -14.59%
Maintains: In-Line
Price Target: $7$2
Current: $1.19
Upside: +68.35%
Maintains: Outperform
Price Target: $37$33
Current: $14.79
Upside: +123.12%
Maintains: Outperform
Price Target: $50$38
Current: $53.77
Upside: -29.33%
Upgrades: Outperform
Price Target: $60$80
Current: $33.53
Upside: +138.59%
Initiates: Outperform
Price Target: $18
Current: $12.44
Upside: +44.69%
Maintains: Outperform
Price Target: $14$25
Current: $3.95
Upside: +532.91%
Initiates: Outperform
Price Target: $35
Current: $5.86
Upside: +497.27%
Initiates: Outperform
Price Target: $24
Current: $29.22
Upside: -17.86%
Reinstates: Outperform
Price Target: $30
Current: $14.25
Upside: +110.53%
Upgrades: Market Outperform
Price Target: $10
Current: $4.36
Upside: +129.36%